The trading price of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) closed lower on Tuesday, July 16, closing at $10.67, -0.93% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $13.17 and a 52-week low of $1.76. Over the past month, the stock has gained 14.24% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc, whose market valuation is $1.24 billion at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest ARQT has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that ARQT’s price is currently 12.71% off the SMA20 and 20.59% off the SMA50. The RSI metric on the 14-day chart is currently showing 62.72, and weekly volatility stands at 9.53%. When measured over the past 30 days, the indicator reaches 8.72%. Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s beta value is currently sitting at 1.19, while the Average True Range indicator is currently displaying 0.80.
To see how Arcutis Biotherapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: ARQT stock’s performance was -0.93% in the latest trading, and 13.03% in the past year.
An evaluation of the daily trading volume of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) indicates that the 3-month average is 2.98 million.
Currently, records show that 115.76 million of the company’s shares remain outstanding. The insiders hold 14.29% of outstanding shares, whereas institutions hold 98.48%. However, since the stock’s price has seen 230.34% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
